Covid-19 Biobank of clinical samples and data for use in research to help understand the immune characteristics of people who are diagnosed with COVID19.

Covid-19 Biobank: a clinical database and biological bank of clinical samples from individuals with COVID-19 infection to better characterise the clinical course and pathogenesis of the infection and provide insights into potential therapeutic agents

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12620000609954

Enrollment

328

Registered

2020-05-25

Start date

2020-04-16

Completion date

2022-02-14

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Establish a clinical database and biological bank of clinical samples from individuals with COVID-19 infection to better characterise the clinical course and pathogenesis of the infection and provide insights into potential therapeutic agents. Individuals that provide consent to give additional samples of blood and nose/throat swabs will be referred to as the intensive sampling group. This group will be recruited when they are hospital inpatients or from the community if they have been diagnosed with COVID-19 and not been admitted to hospital. These individuals will also consent to clinical data being collected from their medical record and any residual samples obtained for routine clinical care being stored in the Bio-bank.. Individuals who are unable to provide informed consent will be referred to as the observational group; these may consist of individuals who have been identified following hospital discharge that are not able to be contacted to be consented for intensive sampling . These individuals will have clinical data collected from the medical record retrospectively and any residual samples obtained from clinical care also being stored in the bio-bank. Individuals for whom no residual specimens are available will not be included in this study.

Interventions

Establish a clinical database and biological bank of clinical samples from individuals with COVID-19 infection to better characterise the clinical course and pathogenesis of the infection and provide insights into potential therapeutic agents. There are two groups 1-intensive sampling group- requires consent to have samples (viral nasal/throat swab and blood for plasma and PBMCs) collected up to 6 time points-from date of COVID-19 diagnosis (0, day 3, day 7, day14-28, 3-6month, & 9-12months. Samples are collected in both the inpatients and community setting. Clinical data and health outcomes data is collected at each time point from data linkage to patient medical records or directly from the participant. 2-observational group - waiver of consent, bio banking of remnant/discarded samples taken from the participant from time of COVID19 diagnosis at their health care institution and matched minimal clinical data linkage to patient medical records

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Age greater than or equal to 18 years of age Confirmed COVID-19 infection by nucleic acid testing

Exclusion criteria

none

Outcome results